Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Allergy Therapeutics ( (GB:AGY) ).
Allergy Therapeutics has amended its existing loan agreement with Hayfin, replacing an uncommitted £20m line with a new committed £40m senior secured facility, giving the company £60m of total debt and at least 12 months of working capital. The funding is intended to support operations, the proposed Hong Kong listing and growth initiatives anchored by the German launch of Grassmuno, while simplifying the capital structure by eliminating shareholder debt.
As part of the deal, Hayfin has exercised all previously issued warrants and new subscription rights on a cashless basis, receiving 191,089,599 new shares and ending up with a 3.02% stake in the company. Following admission of these shares to AIM, Allergy Therapeutics’ issued share capital will rise to 6,332,529,550 shares, clarifying the new voting rights base for investors and slightly diluting existing shareholders as the company secures long‑term financing.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £9.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The score is driven primarily by very weak financial performance (declining revenue, large losses, negative cash flows, and negative equity). Technicals are mixed with oversold signals but still negative momentum, and valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company specialising in allergy immunotherapies. The group focuses on developing and marketing treatments for allergic conditions, with recent growth underpinned by the launch of its Grassmuno product in Germany and plans for an international expansion via a potential Hong Kong stock exchange listing.
Average Trading Volume: 338,050
Technical Sentiment Signal: Buy
Current Market Cap: £552.7M
Learn more about AGY stock on TipRanks’ Stock Analysis page.